Sunshine Biopharma (SBFM) AI Stock Analysis

• Market Cap: $6.56M
• Dividend Yield: N/A
• Average Volume (3M): 569.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 35.51%
• EPS Growth: 95.44%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.44
• Shares Outstanding: 4,555,945
• 10 Day Avg. Volume: 128,688
• 30 Day Avg. Volume: 569,341
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.31
• Enterprise Value/Market Cap: -0.64
• Enterprise Value/Revenue: -0.03
• Enterprise Value/Gross Profit: -0.39
• Enterprise Value/Ebitda: 0.26
• 1Y Price Target: $7.00
• Price Target Upside: 386.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: ―

Sunshine Biopharma's stock score is primarily impacted by financial performance challenges, including significant yet unprofitable revenue growth and negative cash flows. Technical analysis indicators suggest bearish momentum, further influencing the negative outlook. Valuation concerns, such as a negative P/E ratio and lack of dividend yield, also weigh on the score. The company needs to address operational inefficiencies and improve profitability to enhance its stock performance.

Sunshine Biopharma Business Overview & Revenue Model

Company Description

Sunshine Biopharma (SBFM) is a biopharmaceutical company engaged in the research, development, and commercialization of oncology and antiviral drugs. The company focuses on developing proprietary drugs to treat various forms of cancer and other serious conditions. Sunshine Biopharma aims to address unmet medical needs through innovative therapies and leverages its scientific expertise to bring effective solutions to the market.

How the Company Makes Money

Sunshine Biopharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by advancing its drug candidates through clinical trials and ultimately receiving regulatory approval to market these drugs. Upon approval, it can generate revenue from sales of its proprietary drugs. Additionally, Sunshine Biopharma may enter into strategic partnerships or licensing agreements with other pharmaceutical companies, providing opportunities for upfront payments, milestone payments, and royalties based on product sales. These collaborations can significantly contribute to the company's earnings by leveraging the partner's distribution networks and expertise in specific markets.

Sunshine Biopharma Financial Statement Overview

Summary

Sunshine Biopharma demonstrates significant revenue growth, indicating market expansion. However, persistent profitability challenges, negative net income, and cash flow issues highlight the need for strategic improvements in cost management and operational efficiency. The balance sheet is stable, but the company must enhance its cash flow and achieve profitability to improve financial health and shareholder value.

Income Statement

Sunshine Biopharma has shown substantial revenue growth over the years, with a significant increase from $21,121 in 2019 to $34,874,283 in 2024. However, the company remains unprofitable, as indicated by negative EBIT, EBITDA, and net income figures across all years, which highlights ongoing operational challenges and cost management issues. The gross profit margin has improved, yet net profit margins remain negative, reflecting a need for better cost control and efficiency to reach profitability.

Balance Sheet

The balance sheet reveals a strong equity position with positive stockholders' equity in recent years, indicating some financial stability. However, the company has experienced fluctuating total assets and liabilities, and a history of negative equity in earlier years. The absence of debt in the latest period is a positive, yet the company's return on equity remains negative, which reflects ongoing profitability issues impacting shareholder value.

Cash Flow

Sunshine Biopharma's cash flow statement highlights a consistent struggle with negative operating and free cash flows, pointing to challenges in generating cash from its operations. Despite this, the company has managed to secure financing, as seen in positive financing cash flows, which have supported its liquidity. Improvements in free cash flow growth are necessary to ensure long-term sustainability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
34.87M	24.09M	4.35M	228.43K	71.41K
	Gross Profit
10.67M	8.34M	1.70M	110.60K	45.56K
	EBIT
-5.81M	-4.79M	-8.67M	-2.44M	-576.87K
	EBITDA
-5.15M	-3.82M	-26.45M	-12.09M	-2.60M
	Net Income Common Stockholders
-5.13M	-4.51M	-26.74M	-12.77M	-897.68K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.69M	16.29M	21.83M	2.05M	989.89K
	Total Assets
30.56M	27.35M	29.24M	2.20M	1.05M
	Total Debt
952.48K	657.71K	4.27M	1.90M	1.91M
	Net Debt
-8.73M	-15.63M	-17.55M	-145.17K	923.23K
	Total Liabilities
7.06M	6.14M	7.62M	1.99M	2.00M
	Stockholders Equity
23.50M	21.21M	21.63M	211.66K	-954.84K
Cash Flow		Free Cash Flow
-14.85M	-9.56M	-5.55M	-1.83M	-658.49K
	Operating Cash Flow
-12.53M	-8.78M	-5.25M	-1.83M	-657.30K
	Investing Cash Flow
-2.32M	-656.15K	-14.62M	0.00	-1.19K
	Financing Cash Flow
9.29M	3.43M	39.47M	2.90M	1.61M

Sunshine Biopharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Neutral. The current price of 1.44 is above the 20-day moving average (MA) of 1.37, below the 50-day MA of 1.59, and below the 200-day MA of 2.50, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.45 is Neutral, neither overbought nor oversold. The STOCH value of 55.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SBFM.

Sunshine Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.23	-45.01%	2.85%	17.55%	-0.69%
SNOA	49 Neutral	$5.19M	―	-64.83%	―	13.51%	78.93%
EVOK	46 Neutral	$5.61M	―	-108.77%	―	97.84%	82.99%
SBFM	40 Underperform	$6.56M	―	-21.17%	―	35.51%	95.44%
RDHL	38 Underperform	$4.22M	―	1155.92%	―	―	―
CPHI	37 Underperform	$7.24M	―	-59.14%	―	-33.10%	71.37%
PRFX	34 Underperform	$3.97M	―	-129.08%	―	―	9.41%

Sunshine Biopharma Corporate Events

Sunshine Biopharma Strengthens Leadership with New Executive Agreements

Sunshine Biopharma Inc. has solidified its leadership team with new employment agreements for its top executives, effective January 1, 2024. Dr. Steve N. Slilaty, CEO, Camille Sebaaly, CFO, and Dr. Abderrazzak Merzouki, COO, will receive annual salary hikes tied to inflation or a minimum increase, whichever is higher. In case of termination without cause, substantial severance packages are promised, ensuring stability and confidence in the company’s future growth strategies.